- Home
- PDEX vs ATOS Comparison
PDEX vs ATOS Comparison
Compare PDEX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDEX
- ATOS
- Stock Information
- Founded
- PDEX 1978
- ATOS 2009
- Country
- PDEX United States
- ATOS United States
- Employees
- PDEX N/A
- ATOS N/A
- Industry
- PDEX Medical/Dental Instruments
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- PDEX Health Care
- ATOS Health Care
- Exchange
- PDEX Nasdaq
- ATOS Nasdaq
- Market Cap
- PDEX 117.9M
- ATOS 96.8M
- IPO Year
- PDEX N/A
- ATOS 2012
- Fundamental
- Price
- PDEX $51.40
- ATOS $0.65
- Analyst Decision
- PDEX Strong Buy
- ATOS Strong Buy
- Analyst Count
- PDEX 1
- ATOS 3
- Target Price
- PDEX $52.00
- ATOS $7.00
- AVG Volume (30 Days)
- PDEX 41.3K
- ATOS 520.3K
- Earning Date
- PDEX 05-01-2025
- ATOS 03-25-2025
- Dividend Yield
- PDEX N/A
- ATOS N/A
- EPS Growth
- PDEX 128.87
- ATOS N/A
- EPS
- PDEX 1.93
- ATOS N/A
- Revenue
- PDEX $61,004,000.00
- ATOS N/A
- Revenue This Year
- PDEX $28.63
- ATOS N/A
- Revenue Next Year
- PDEX $3.09
- ATOS N/A
- P/E Ratio
- PDEX $26.58
- ATOS N/A
- Revenue Growth
- PDEX 26.45
- ATOS N/A
- 52 Week Low
- PDEX $16.84
- ATOS $0.65
- 52 Week High
- PDEX $59.60
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- PDEX 67.45
- ATOS 31.82
- Support Level
- PDEX $47.00
- ATOS $0.66
- Resistance Level
- PDEX $52.00
- ATOS $0.71
- Average True Range (ATR)
- PDEX 2.56
- ATOS 0.04
- MACD
- PDEX 0.05
- ATOS -0.00
- Stochastic Oscillator
- PDEX 91.84
- ATOS 0.00
About PDEX Pro-Dex Inc.
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.